Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00608985




Registration number
NCT00608985
Ethics application status
Date submitted
11/01/2008
Date registered
6/02/2008
Date last updated
14/03/2016

Titles & IDs
Public title
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
Scientific title
Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group Polysomnography Study to Assess the Efficacy and Safety of a 16-day Oral Administration of ACT-078573 in Adult Subjects With Chronic Primary Insomnia
Secondary ID [1] 0 0
AC-057A301
Universal Trial Number (UTN)
Trial acronym
RESTORA 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Primary Insomnia 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - almorexant
Treatment: Drugs - almorexant
Treatment: Drugs - Placebo
Treatment: Drugs - zolpidem

Experimental: 1 - almorexant 200 mg

Experimental: 2 - almorexant 100 mg

Placebo Comparator: 3 - Placebo

Active Comparator: 4 - zolpidem 10 mg


Treatment: Drugs: almorexant
2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem

Treatment: Drugs: almorexant
1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem

Treatment: Drugs: Placebo
2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem

Treatment: Drugs: zolpidem
2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline to Day 1&2 in Wake After Sleep Onset (WASO)
Timepoint [1] 0 0
From baseline to Day 1&2
Primary outcome [2] 0 0
Change From Baseline to Day 15&16 in WASO
Timepoint [2] 0 0
From baseline to Day 15&16
Primary outcome [3] 0 0
Change From Baseline to Week 1&2 in the Self-reported WASO (sWASO)
Timepoint [3] 0 0
From baseline to Week 1&2
Secondary outcome [1] 0 0
Change From Baseline to Day 1&2 in Latency to Persistent Sleep (LPS)
Timepoint [1] 0 0
From baseline to Day 1&2
Secondary outcome [2] 0 0
Change From Baseline to Day 15&16 in LPS
Timepoint [2] 0 0
From baseline to Day 15&16
Secondary outcome [3] 0 0
Change From Baseline to Week 1&2 in Subjective Latency to Sleep Onset (sLSO)
Timepoint [3] 0 0
From baseline to Week 1&2

Eligibility
Key inclusion criteria
- Adult subjects (18-64 years) with a diagnosis of primary insomnia.
Minimum age
18 Years
Maximum age
64 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV) axis I disorder other than primary insomnia.

- Sleep apnea, or restless legs syndrome.

- Daytime napping of more than 1 hour per day.

- Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2
years prior to the screening visit.

- Unwillingness to refrain from drugs, over-the-counter or herbal medication having an
effect on sleep or behavior.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2009
Sample size
Target
Accrual to date
Final
709
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 0 0
Sleep Disorders Laboratory, Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Monash Adult Sleep Center, Monash Medical Centre - Clayton
Recruitment hospital [3] 0 0
Western Hospitpal, Private Bag - Footscray
Recruitment hospital [4] 0 0
Institute for Breathing and Sleep (IBAS) - Heidelburg
Recruitment hospital [5] 0 0
The Woolcock Institute of Medical Research - Glebe
Recruitment hospital [6] 0 0
Australian Clinical Research Organisation - Kippa Ring
Recruitment hospital [7] 0 0
Melbourne Sleep Disorder Centre - Melbourne
Recruitment hospital [8] 0 0
Burnside Hospital Clinical Trials Centre - Toorak Gardens
Recruitment hospital [9] 0 0
Westmead Hospital, Department of Respiratory - Westmead
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3011 - Footscray
Recruitment postcode(s) [4] 0 0
3084 - Heidelburg
Recruitment postcode(s) [5] 0 0
2050 - Glebe
Recruitment postcode(s) [6] 0 0
4021 - Kippa Ring
Recruitment postcode(s) [7] 0 0
- Melbourne
Recruitment postcode(s) [8] 0 0
5065 - Toorak Gardens
Recruitment postcode(s) [9] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Innsbruck
Country [2] 0 0
Austria
State/province [2] 0 0
Vienna
Country [3] 0 0
Belgium
State/province [3] 0 0
Brussels
Country [4] 0 0
Belgium
State/province [4] 0 0
Haine Saint Paul
Country [5] 0 0
Belgium
State/province [5] 0 0
Montigny le Tilleuil
Country [6] 0 0
Bulgaria
State/province [6] 0 0
Sofia
Country [7] 0 0
Bulgaria
State/province [7] 0 0
Varna
Country [8] 0 0
Czech Republic
State/province [8] 0 0
Ceske Budejovice
Country [9] 0 0
Czech Republic
State/province [9] 0 0
Katerinska
Country [10] 0 0
Czech Republic
State/province [10] 0 0
Ostava-Poruba
Country [11] 0 0
Czech Republic
State/province [11] 0 0
Prague
Country [12] 0 0
Czech Republic
State/province [12] 0 0
Trutnov
Country [13] 0 0
Denmark
State/province [13] 0 0
Arhus
Country [14] 0 0
Denmark
State/province [14] 0 0
Copenhagen
Country [15] 0 0
Finland
State/province [15] 0 0
Helsinki
Country [16] 0 0
Finland
State/province [16] 0 0
Tampere
Country [17] 0 0
Finland
State/province [17] 0 0
Turku
Country [18] 0 0
France
State/province [18] 0 0
Bordeaux
Country [19] 0 0
France
State/province [19] 0 0
Garches
Country [20] 0 0
France
State/province [20] 0 0
Montpellier
Country [21] 0 0
France
State/province [21] 0 0
Paris
Country [22] 0 0
Germany
State/province [22] 0 0
Berlin
Country [23] 0 0
Germany
State/province [23] 0 0
Bochum
Country [24] 0 0
Germany
State/province [24] 0 0
Chemnitz
Country [25] 0 0
Germany
State/province [25] 0 0
Dresden
Country [26] 0 0
Germany
State/province [26] 0 0
Frankfurt
Country [27] 0 0
Germany
State/province [27] 0 0
Freiburg
Country [28] 0 0
Germany
State/province [28] 0 0
Gorlitz
Country [29] 0 0
Germany
State/province [29] 0 0
Hamburg
Country [30] 0 0
Germany
State/province [30] 0 0
Leipzig
Country [31] 0 0
Germany
State/province [31] 0 0
Magdeburg
Country [32] 0 0
Germany
State/province [32] 0 0
Marburg
Country [33] 0 0
Germany
State/province [33] 0 0
Potsdam
Country [34] 0 0
Germany
State/province [34] 0 0
Regensburg
Country [35] 0 0
Germany
State/province [35] 0 0
Schwerin
Country [36] 0 0
Hungary
State/province [36] 0 0
Budapest
Country [37] 0 0
Hungary
State/province [37] 0 0
Debrecen
Country [38] 0 0
Hungary
State/province [38] 0 0
Pecs
Country [39] 0 0
Hungary
State/province [39] 0 0
Szeged
Country [40] 0 0
Israel
State/province [40] 0 0
Beer Sheva
Country [41] 0 0
Israel
State/province [41] 0 0
Haifa
Country [42] 0 0
Italy
State/province [42] 0 0
Bologna
Country [43] 0 0
Italy
State/province [43] 0 0
Milan
Country [44] 0 0
Italy
State/province [44] 0 0
Pisa
Country [45] 0 0
Poland
State/province [45] 0 0
Gdansk
Country [46] 0 0
Poland
State/province [46] 0 0
Krakow
Country [47] 0 0
Poland
State/province [47] 0 0
Lodz
Country [48] 0 0
Poland
State/province [48] 0 0
Warsaw
Country [49] 0 0
Poland
State/province [49] 0 0
Warszawa
Country [50] 0 0
Poland
State/province [50] 0 0
Wroclaw
Country [51] 0 0
Slovakia
State/province [51] 0 0
Bratislava
Country [52] 0 0
Slovakia
State/province [52] 0 0
Kosice
Country [53] 0 0
South Africa
State/province [53] 0 0
Johannesburg
Country [54] 0 0
South Africa
State/province [54] 0 0
Western Cape
Country [55] 0 0
South Africa
State/province [55] 0 0
Pretoria
Country [56] 0 0
South Africa
State/province [56] 0 0
Somerset West
Country [57] 0 0
Spain
State/province [57] 0 0
Barcelona
Country [58] 0 0
Spain
State/province [58] 0 0
Madrid
Country [59] 0 0
Spain
State/province [59] 0 0
Palma de Mallorca
Country [60] 0 0
Spain
State/province [60] 0 0
Valencia
Country [61] 0 0
Spain
State/province [61] 0 0
Zaragoza
Country [62] 0 0
Sweden
State/province [62] 0 0
Goteborg
Country [63] 0 0
Sweden
State/province [63] 0 0
Orebro
Country [64] 0 0
Sweden
State/province [64] 0 0
Stockholm
Country [65] 0 0
Switzerland
State/province [65] 0 0
Basel
Country [66] 0 0
Switzerland
State/province [66] 0 0
Chene-Bourg
Country [67] 0 0
Switzerland
State/province [67] 0 0
Lucerne
Country [68] 0 0
Switzerland
State/province [68] 0 0
Zurich
Country [69] 0 0
Switzerland
State/province [69] 0 0
Zurzach
Country [70] 0 0
Ukraine
State/province [70] 0 0
Kiev
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Edinburgh
Country [72] 0 0
United Kingdom
State/province [72] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Midnight Pharma, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A polysomnography study to evaluate the effect, safety and tolerability of oral
administration of almorexant (ACT 078573) in adult subjects with primary insomnia.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00608985
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Raymond Cluydts, Dr.
Address 0 0
Cognitive and Biological Psychology, University of Brussels
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00608985